Research on Reprimo,hMLH1 Gene Methylation in Early Diagnosis Value of Gastric Cancer
10.3969/j.issn.1671-7414.2015.03.015
- VernacularTitle:Reprimo 和 hMLH1基因甲基化在胃癌早期诊断价值的研究
- Author:
Ying LI
;
Mo YI
;
Xiaoqin HE
- Publication Type:Journal Article
- Keywords:
Reprimo gene;
hMLH1 gene;
early diagnosis of gastric cancer
- From:
Journal of Modern Laboratory Medicine
2015;(3):53-55,59
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the Reprimo and hMLH1 gene promoter methylation detection value in the diagnosis of early gastric cancer.Methods Chose patints in Shaanxi Provincial People’s Hospital from September 2013 to April 2014,50 cases of patients with chronic atrophicgastritis with intestinal metaplasia,50 cases of patients with gastricmucosal atypical hyperplasia,50 patients with gastric cancer,endoscopic gastric biopsy samples,and 30 cases of normal gastric mucosa biopsy tissues as control group.Analysis abnormal expression in Reprimo gene and hMLH1 genes promoter methylation,compared the differences.between groups of patients.Results The patients with gastric mucosatissues Reprimo and hMLH1 genes promoter methylation positive rate was significantly higher than that of normal group,the difference wasstatistically signifi-cant (P<0.05).Reprimo gene promoter methylation were:patients with chronic atrophic gastritis with intestinal metaplasia 28% (χ2 =10.18,P < 0.05).Patients with gastric mucosalatypical hyperplasia 56% (χ2 = 25.84,P < 0.05)and patients with gastric cancer 62% (χ2 = 30.36,P < 0.05).hMLH1 gene promoter methylation were:patients with chronic atrophic gastritis with intestinal metaplasia 20% (χ2 =4.39,P <0.05),patients with gastric mucosal atypical hyperplasia 44% (χ2 =15.13,P <0.05)and patients with gastric cancer 48% (χ2 = 17.41,P <0.05),high specificity of detection.Conclusion Reprimo and hMLH1 gene’s detect value in the diagnosis of early gastric cancer is very high,high specificity,it is an effec-tive way of diagnosis,treatment in clinical diagnosis of patients with broad prospects.